STAT3 and hepatocellular carcinoma: Because inhibiting STAT3 pathway was recently found to improve the efficacy of anti-PD-1/PD-L1 treatment,30, 31 we evaluated the combinatorial effect of DDK inhibitor and anti-PD-1 antibody in HCC-bearing murine models.